Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer | RVX.TO Message Board Posts

Resverlogix Corp.

  RVX.TO website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

RVX.TO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  27125 of 27126  at  6/30/2020 8:05:00 AM  by

rndtbl

The following message was updated on 6/30/2020 8:42:37 AM.

Combination of ZEN-3694 with CDK4/6 inhibitors reverses resistance in ER-positive breast cancer

 https://pressfrom.info/au/lifestyle/health/-230957-lillys-breast-cancer-drug-succeeds-in-study-shares-rise-11.html
         6/17/20

Eli Lilly and Co said on Tuesday its treatment, Verzenio, met the trial goal of reducing the risk of early-stage breast cancer returning, sending the company's shares up 11%. The treatment, also known as abemaciclib, is approved to treat certain forms of breast cancer but not prevent cancer from recurring, and analysts estimate the data could add billions to its sales.

About 30% of patients with a common subtype of early breast cancer that the drug targets are at a high-risk of their cancer returning, despite progress in the treatment.

In May, an independent data monitoring committee said rival Pfizer Inc's drug, Ibrance, was unlikely to meet the main goal of a study testing it in early breast cancer patients.

The late-stage trial data on Verzenio delivering a reduced risk of breast cancer recurrence or death comes earlier than expected and sets up the drug to have an expanded approval by roughly the middle of next year, said Mizuho analyst Vamil Divan.

Eli Lilly said it would submit the data from the trial to regulatory authorities before the end of 2020.

Breast cancer is the second most common cancer among women in the United States with black women dying from the disease at a higher rate than white women, according to the U.S. Centers for Disease Control and Prevention.

 
 https://www.marketbeat.com/instant-alerts/nyse-lly-a-buy-or-sell-right-now/
 6/29/20
Eli Lilly And Co (NYSE:LLY) had its price objective upped by stock analysts at Mizuho from $155.00 to $164.00 in a research report issued on Monday, The Fly reports. The firm currently has a "neutral" rating on the stock. Mizuho's price objective points to a potential upside of 0.72% from the company's previous close. 
 
6/29/20
https://www.zenithepigenetics.com/upload/media_element/120/01/aacr-2020-1750-abstract-2346.pdf 
 
 
 
 
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 113
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...